# BIOQL – Strategic Partnership & Valuation Brief

Executive Negotiation Summary – October 2025

## 1. Real Valuation & Core Strength

BioQL is a proprietary natural language to quantum code (NL→QC) compiler designed for next-generation drug discovery and CRISPR optimization. The platform integrates six quantum backends (IBM, IonQ, Google, AWS, Azure, Rigetti) and a full nine-step pipeline powered by the Bio-HNET 4.5B AI model.

• Current Valuation: USD 15–25M pre-money  
• Strategic Value: USD 50–200M  
• Codebase: 56K+ lines, 142 modules, 14 cores  
• Gross Margin: 99% (SaaS)  
• Active Clients: 9 paying customers, validated on real quantum hardware  
• IP Portfolio: 3–5 patentable modules (Quantum algorithms + CRISPR-QAI)  
• Replacement Cost: > USD 3M in R&D value

## 2. Growth & Commercialization Outlook

BioQL is transitioning from validation to rapid scaling, with a defined path to $1B+ valuation in 3–5 years:

|  |  |  |  |
| --- | --- | --- | --- |
| Timeline | Key Milestone | Projected ARR | Valuation Range (10–25x ARR) |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| 12 months | 100 clients | $1.2M | $12–30M |
| 24 months | 500 clients | $12M | $120–300M |
| 36 months | 1,500 clients | $90M | $900M–2.25B |

## 3. Expected Role of InoSwift Venture Studio

InoSwift’s role is that of a strategic accelerator — not an acquirer — contributing tangible financial and strategic value:

• Upfront Technology Access Fee: USD 350,000 (cash) for a 90-day evaluation license  
• Value Contribution: investor introductions, GTM support, and Series Seed/A fundraising alignment  
• No equity dilution below USD 15M pre-money valuation  
• Future co-developments to follow revenue-share or equity-for-service terms only above that baseline

## 4. Partnership Framework

1. Spectrix retains 100% of BioQL IP ownership.  
2. InoSwift gains temporary, limited access for evaluation.  
3. All future ventures must reference the USD 15–25M valuation baseline.  
4. $350K upfront cash ensures strategic alignment and fair compensation.

## 5. Conclusion

BioQL stands as one of the most advanced and commercially validated quantum-AI platforms in biotech. InoSwift’s participation must begin with a USD 350K upfront contribution, establishing a fair and strategic foundation for future co-development.